Latest news
Capsule inhaler ICOcap™ from Iconovo CE-marked for clinical trials
Iconovo announce that the capsule-based dry powder inhaler ICOcap™ is CE-marked for use in clinical trials
ICOcap™ is now available for customers…
Market analysis of Iconovo by Danske Bank
Stepping closer to important milestones
Iconovo’s Q1 results were confirmatory for us. Since mid-April, Iconovo has had a new CEO, Johan Wäborg, with…
Press releases
Apr 24, 2026, 09:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Apr 23, 2026, 16:40
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 14, 2026, 15:40
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Staff change
Apr 14, 2026, 15:40
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Staff change
Mar 17, 2026, 16:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 17, 2026, 16:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 10, 2026, 08:05
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Mar 02, 2026, 16:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 27, 2026, 18:20
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 24, 2026, 20:50
News
IR
Swedish
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 24, 2026, 20:50
News
IR
English
Corporate Action
Other
mfn-ext-nq
mfn-ext-nq-corporate-action
Feb 13, 2026, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 13, 2026, 08:30
News
IR
English
Regulatory
Listing Regulation
Corporate Information
Other Corporate Information
mfn-cus-top-disclaimer
mfn-ext-nq
mfn-ext-nq-listing
Feb 12, 2026, 14:30
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Prospectus
Feb 12, 2026, 14:30
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Prospectus
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
CEO
Anders Månsson
Mail: anders.mansson@iconovo.se